DanThe failure rate of stage 2 and 3 clinical trials due to poor...

Dan
The failure rate of stage 2 and 3 clinical trials due to poor efficacy is high - P3 is over 54%.
IMM phase 2b efficacy data is disappointing for sure. Thus far......wait for OS
Must admit I was lower than a snakes belly after announcement. It's a tough business.
Market cap smashed and retail holders (generalisation) run for the hills.
A New approved drug takes up to 10 years and average cost over $2 billion to get to market.
IMM is not PRR and the strategy is to develop multiple products and license out to big pharma
Objective- multiple income streams that fund development of novel immuno - oncology and autoimmune drugs
AND provide shareholders with a great return on investment- dividends.
Definitely a set-back with AIPAC trial but the real anomaly is the placebo arm not Efti that performed as expected.
Thomas Edison didn't give up after his first light bulb didn't work - that said Immutep do not have as many chances to prove Efti works.
TACTI-002 looking great.
Updated data soon if positive would help sentiment- if not positive, game over imo